Delivering cost–effective care for COPD in the USA: recent progress and current challenges

References

• Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011. 2012(07/17). (2011).
   Google Scholar
• National Heart, Lung, and Blood Institute. Morbidity and mortality: 2012 chart book on cardiovascular, lung, and blood diseases. 2012(07/17). (2012).
   Google Scholar
• Sandelowsky H, Ställberg B, Nager A, Hasselström J. The prevalence of undiagnosed chronic obstructive pulmonary disease in a primary care population with respiratory tract infections – a case finding study. BMC Fam. Pract. 12, 122 (2011).
   PubMed Web of Science ®Google Scholar
• Akazawa M, Halpern R, Riedel AA, Stanford RH, Dalal A, Blanchette CM. Economic burden prior to COPD diagnosis: a matched case–control study in the United States. Respir. Med. 102(12), 1744–1752 (2008).
   PubMed Web of Science ®Google Scholar
• Miniño AM, Xu J, Kochanek KD. Deaths: preliminary data for 2008. Natl Vital Stat. Rep. 59(2) (2010).
   PubMedGoogle Scholar
• DiBonaventura Md, Paulose-Ram R, Su J et al. The burden of chronic obstructive pulmonary disease among employed adults. Int. J. Chron. Obstruct. Pulmon. Dis. 7, 211–219 (2012).
   PubMed Web of Science ®Google Scholar
• Darkow T, Kadlubek PJ, Shah H, Phillips AL, Marton JP. A retrospective analysis of disability and its related costs among employees with chronic obstructive pulmonary disease. J. Occup. Environ. Med. 49(1), 22–30 (2007).
   PubMed Web of Science ®Google Scholar
• Sin DD, Stafinski T, Ng YC, Bell NR, Jacobs P. The impact of chronic obstructive pulmonary disease on work loss in the United States. Am. J. Respir. Crit. Care Med. 165(5), 704–707 (2002).
   PubMed Web of Science ®Google Scholar
• National Heart, Lung, and Blood Institute. Morbidity and mortality: 2009 chart book on cardiovascular, lung, and blood diseases. (2012).
   Google Scholar
• Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet 370(9589), 786–796 (2007).
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest 117(2 Suppl.), 5S–9S (2000).
   PubMed Web of Science ®Google Scholar
• Stuart B, Doshi JA, Briesacher B, Wrobel MV, Baysac F. Impact of prescription coverage on hospital and physician costs: a case study of medicare beneficiaries with chronic obstructive pulmonary disease. Clin. Ther. 26(10), 1688–1699 (2004).
   PubMed Web of Science ®Google Scholar
• Miller JD, Foster T, Boulanger L et al. Direct costs of COPD in the US: an analysis of Medical Expenditure Panel Survey (MEPS) data. COPD 2(3), 311–318 (2005).
   PubMedGoogle Scholar
• Marton JP, Boulanger L, Friedman M, Dixon D, Wilson J, Menzin J. Assessing the costs of chronic obstructive pulmonary disease: the state medicaid perspective. Respir. Med. 100(6), 996–1005 (2006).
   PubMed Web of Science ®Google Scholar
• Halpern MT, Stanford RH, Borker R. The burden of COPD in the USA: results from the Confronting COPD survey. Respir. Med. 97(Suppl. C), S81–S89 (2003).
   PubMed Web of Science ®Google Scholar
• Hilleman DE, Dewan N, Malesker M, Friedman M. Pharmacoeconomic evaluation of COPD. Chest 118(5), 1278–1285 (2000).
   PubMed Web of Science ®Google Scholar
• Foster TS, Miller JD, Marton JP, Caloyeras JP, Russell MW, Menzin J. Assessment of the economic burden of COPD in the US: a review and synthesis of the literature. COPD 3(4), 211–218 (2006).
   PubMedGoogle Scholar
• Dalal AA, Liu F, Riedel AA. Cost trends among commercially insured and Medicare Advantage-insured patients with chronic obstructive pulmonary disease: 2006 through 2009. Int. J. Chron. Obstruct. Pulmon. Dis. 6, 533–542 (2011).
   PubMed Web of Science ®Google Scholar
• Strassels SA, Smith DH, Sullivan SD, Mahajan PS. The costs of treating COPD in the United States. Chest 119(2), 344–352 (2001).
   PubMed Web of Science ®Google Scholar
• Yawn BP, Raphiou I, Hurley JS, Dalal AA. The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 5, 165–178 (2010).
   PubMedGoogle Scholar
• Simoens S, Decramer M. Pharmacoeconomics of the management of acute exacerbations of chronic obstructive pulmonary disease. Expert Opin. Pharmacother. 8(5), 633–648 (2007).
   PubMed Web of Science ®Google Scholar
• Mapel DW, Schum M, Lydick E, Marton JP. A new method for examining the cost savings of reducing COPD exacerbations. Pharmacoeconomics 28(9), 733–749 (2010).
   PubMed Web of Science ®Google Scholar
• Halpin DM. Lessons from the major studies in COPD: problems and pitfalls in translating research evidence into practice. Prim. Care Respir. J. 19(2), 170–179 (2010).
   PubMedGoogle Scholar
• Urbano FL, Pascual RM. Contemporary issues in the care of patients with chronic obstructive pulmonary disease. J. Manag. Care Pharm. 11(5 Suppl. A), S2–13; quiz S14 (2005).
   PubMedGoogle Scholar
• Donner CF, Virchow JC, Lusuardi M. Pharmacoeconomics in COPD and inappropriateness of diagnostics, management and treatment. Respir. Med. 105(6), 828–837 (2011).
   PubMedGoogle Scholar
• Hanania NA. Optimizing maintenance therapy for chronic obstructive pulmonary disease: strategies for improving patient-centered outcomes. Clin. Ther. 29(10), 2121–2133 (2007).
   PubMed Web of Science ®Google Scholar
• Anzueto A. Clinical course of chronic obstructive pulmonary disease: review of therapeutic interventions. Am. J. Med. 119(10 Suppl. 1), 46–53 (2006).
   PubMedGoogle Scholar
• Wise RA, Tashkin DP. Optimizing treatment of chronic obstructive pulmonary disease: an assessment of current therapies. Am. J. Med. 120(8 Suppl. 1), S4–13 (2007).
   PubMedGoogle Scholar
• Albert RK, Connett J, Bailey WC et al.; COPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD. N. Engl. J. Med. 365(8), 689–698 (2011).
   PubMed Web of Science ®Google Scholar
• Rennard SI, Calverley PM, Goehring UM, Bredenbröker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor roflumilast – the importance of defining different subsets of patients with COPD. Respir. Res. 12, 18 (2011).
   PubMed Web of Science ®Google Scholar
• Lareau SC, Hodder R. Teaching inhaler use in chronic obstructive pulmonary disease patients. J. Am. Acad. Nurse Pract. 24(2), 113–120 (2012).
   PubMed Web of Science ®Google Scholar
• Lareau SC, Yawn BP. Improving adherence with inhaler therapy in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 5, 401–406 (2010).
   PubMedGoogle Scholar
• Charles MS, Blanchette CM, Silver H, Lavallee D, Dalal AA, Mapel D. Adherence to controller therapy for chronic obstructive pulmonary disease: a review. Curr. Med. Res. Opin. 26(10), 2421–2429 (2010).
   PubMed Web of Science ®Google Scholar
• Restrepo RD, Alvarez MT, Wittnebel LD et al. Medication adherence issues in patients treated for COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 3(3), 371–384 (2008).
   PubMedGoogle Scholar
• Lemmens KM, Nieboer AP, Huijsman R. A systematic review of integrated use of disease-management interventions in asthma and COPD. Respir. Med. 103(5), 670–691 (2009).
   PubMed Web of Science ®Google Scholar
• Clark NM, Dodge JA, Partridge MR, Martinez FJ. Focusing on outcomes: making the most of COPD interventions. Int. J. Chron. Obstruct. Pulmon. Dis. 4, 61–77 (2009).
   PubMedGoogle Scholar
• Nici L, Raskin J, Rochester CL et al. Pulmonary rehabilitation: what we know and what we need to know. J. Cardiopulm. Rehabil. Prev. 29(3), 141–151 (2009).
   PubMed Web of Science ®Google Scholar
• Nici L, Lareau S, ZuWallack R. Pulmonary rehabilitation in the treatment of chronic obstructive pulmonary disease. Am. Fam. Physician 82(6), 655–660 (2010).
   PubMed Web of Science ®Google Scholar
• Steuten LM, Lemmens KM, Nieboer AP, Vrijhoef HJ. Identifying potentially cost effective chronic care programs for people with COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 4, 87–100 (2009).
   PubMedGoogle Scholar
• Casaburi R, Kukafka D, Cooper CB, Witek TJ Jr, Kesten S. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 127(3), 809–817 (2005).
   PubMed Web of Science ®Google Scholar
• Lin PJ, Shaya FT, Scharf SM. Economic implications of comorbid conditions among Medicaid beneficiaries with COPD. Respir. Med. 104(5), 697–704 (2010).
   PubMed Web of Science ®Google Scholar
• Hurst JR, Wedzicha JA. Management and prevention of chronic obstructive pulmonary disease exacerbations: a state of the art review. BMC Med. 7, 40 (2009).
   PubMed Web of Science ®Google Scholar
• Linden A, Adler-Milstein J. Medicare disease management in policy context. Health Care Financ. Rev. 29(3), 1–11 (2008).
   PubMed Web of Science ®Google Scholar
• Wilkinson TM, Donaldson GC, Hurst JR, Seemungal TA, Wedzicha JA. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 169(12), 1298–1303 (2004).
   PubMed Web of Science ®Google Scholar
• Akgün KM, Crothers K, Pisani M. Epidemiology and management of common pulmonary diseases in older persons. J. Gerontol. A Biol. Sci. Med. Sci. 67(3), 276–291 (2012).
   PubMed Web of Science ®Google Scholar
• Asche CV, Leader S, Plauschinat C et al. Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids. Int. J. Chron. Obstruct. Pulmon. Dis. 7, 201–209 (2012).
   PubMed Web of Science ®Google Scholar
• Make B, Dutro MP, Paulose-Ram R, Marton JP, Mapel DW. Undertreatment of COPD: a retrospective analysis of US managed care and Medicare patients. Int. J. Chron. Obstruct. Pulmon. Dis. 7, 1–9 (2012).
   PubMed Web of Science ®Google Scholar
• Simoni-Wastila L, Wei YJ, Qian J et al. Association of chronic obstructive pulmonary disease maintenance medication adherence with all-cause hospitalization and spending in a medicare population. Am. J. Geriatr. Pharmacother. 10(3), 201–210 (2012).
   PubMed Web of Science ®Google Scholar
• Toy EL, Beaulieu NU, McHale JM et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir. Med. 105(3), 435–441 (2011).
   PubMed Web of Science ®Google Scholar
• Rutschmann OT, Janssens JP, Vermeulen B, Sarasin FP. Knowledge of guidelines for the management of COPD: a survey of primary care physicians. Respir. Med. 98(10), 932–937 (2004).
   PubMed Web of Science ®Google Scholar
• Shaya FT, Dongyi D, Akazawa MO et al. Burden of concomitant asthma and COPD in a Medicaid population. Chest 134(1), 14–19 (2008).
   PubMed Web of Science ®Google Scholar
• Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. Int. J. Chron. Obstruct. Pulmon. Dis. 4, 337–349 (2009).
   PubMedGoogle Scholar
• Simon-Tuval T, Scharf SM, Maimon N, Bernhard-Scharf BJ, Reuveni H, Tarasiuk A. Determinants of elevated healthcare utilization in patients with COPD. Respir. Res. 12, 7 (2011).
   PubMedGoogle Scholar
• Bustacchini S, Chiatti C, Furneri G, Lattanzio F, Mantovani LG. The economic burden of chronic obstructive pulmonary disease in the elderly: results from a systematic review of the literature. Curr. Opin. Pulm. Med. 17(Suppl. 1), S35–S41 (2011).
   PubMedGoogle Scholar
• Yu AP, Guérin A, de Leon DP et al. Clinical and economic outcomes of multiple versus single long-acting inhalers in COPD. Respir. Med. 105(12), 1861–1871 (2011).
   PubMed Web of Science ®Google Scholar
• Shaya FT, Breunig IM, Scharf SM. The use of age-period-cohort analysis to determine the impact of economic development on COPD mortality in Hong Kong. Expert Rev. Pharmacoecon. Outcomes Res. 12(1), 19–21 (2012).
   PubMed Web of Science ®Google Scholar
• Eisner MD, Blanc PD, Omachi TA et al. Socioeconomic status, race and COPD health outcomes. J. Epidemiol. Community Health 65(1), 26–34 (2011).
   PubMed Web of Science ®Google Scholar
• Castaldi PJ, Rogers WH, Safran DG, Wilson IB. Inhaler costs and medication nonadherence among seniors with chronic pulmonary disease. Chest 138(3), 614–620 (2010).
   PubMed Web of Science ®Google Scholar
• Mauskopf JA, Baker CL, Monz BU, Juniper MD. Cost–effectiveness of tiotropium for chronic obstructive pulmonary disease: a systematic review of the evidence. J. Med. Econ. 13(3), 403–417 (2010).
   PubMedGoogle Scholar
• Akazawa M, Stearns SC, Biddle AK. Assessing treatment effects of inhaled corticosteroids on medical expenses and exacerbations among COPD patients: longitudinal analysis of managed care claims. Health Serv. Res. 43(6), 2164–2182 (2008).
   PubMed Web of Science ®Google Scholar
• Chatterjee A, Shah M, D’Souza AO, Bechtel B, Crater G, Dalal AA. Observational study on the impact of initiating tiotropium alone versus tiotropium with fluticasone propionate/salmeterol combination therapy on outcomes and costs in chronic obstructive pulmonary disease. Respir. Res. 13, 15 (2012).
   PubMed Web of Science ®Google Scholar
• Dalal AA, Shah M, D’Souza AO, Crater GD. Rehospitalization risks and outcomes in COPD patients receiving maintenance pharmacotherapy. Respir. Med. 106(6), 829–837 (2012).
   PubMed Web of Science ®Google Scholar
• Akazawa M, Hayflinger DC, Stanford RH, Blanchette CM. Economic assessment of initial maintenance therapy for chronic obstructive pulmonary disease. Am. J. Manag. Care 14(7), 438–448 (2008).
   PubMed Web of Science ®Google Scholar
• Shaya FT, Maneval MS, Gbarayor CM et al. Burden of COPD, asthma, and concomitant COPD and asthma among adults: racial disparities in a medicaid population. Chest 136(2), 405–411 (2009).
   PubMed Web of Science ®Google Scholar
• Shaya FT, Samant N, Pradel F, Mullins CD, Scharf SM, Britt J. Health-related quality of life as a potential predictor in chronic obstructive lung disease patients. Expert Rev. Pharmacoecon. Outcomes Res. 7(2), 129–135 (2007).
   PubMedGoogle Scholar